Thrombotic events in patients with systemic sclerosis treated with iloprost.
Tedeschi
A
A
IRCCS Ospedale Maggiore Policlinico, Milano, Italy.
Meroni
P L
PL
Del Papa
N
N
Salmaso
C
C
Boschetti
C
C
Miadonna
A
A
D005260:Female; D006801:Humans; D016285:Iloprost / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D013927:Thrombosis / Q000139:chemically induced*; D014665:Vasodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D016285:Iloprost